Document:

Exhibit 10.8

FORWARD PURCHASE AGREEMENT

 

This
Forward Purchase Agreement (this “Agreement”) is entered into as of May ___, 2021, by and between Aries
I Acquisition Corporation., a Cayman Islands exempted company (the “Company”), and the party listed as the purchaser
on the signature page hereof (the “Purchaser”).

 

WHEREAS,
the Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses (a “Business Combination”);

 

WHEREAS,
the Company has filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement
on Form S-1 (the “Registration Statement”) for its initial public offering (“IPO”)
of units (the “Units”) at a price of $10.00 per Unit, each comprised of one Class A ordinary share of the
Company, par value $0.0001 per share (the “Ordinary Share(s)”), and one-half of one redeemable warrant, where
each whole redeemable warrant is exercisable to purchase one Ordinary Share at an exercise price of $11.50 per share (the “Warrant(s)”);

 

WHEREAS,
following the closing of the IPO (the “IPO Closing”), the Company will seek to identify and consummate a Business
Combination; and

 

WHEREAS,
the parties wish to enter into this Agreement, pursuant to which immediately prior to the closing of the Company’s initial Business
Combination (the “Business Combination Closing”), the Company shall issue and sell, and the Purchaser shall
purchase, on a private placement basis, up to $50,000,000 of Ordinary Shares at a price of $10.00 per share (the "Forward Purchase
Shares" or the "Forward Purchase Securities").

 

NOW,
THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree
as follows:

 

1. Sale and Purchase.

 

(a) Forward
Purchase Securities.

 

(i) The
Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, the number of Forward Purchase Shares
that is the quotient of (x) the amount of capital committed by the Purchaser and allocated to this Agreement as notified by the Purchaser
to the Company no later than five (5) Business Days prior to such time as any definitive agreement with respect to a Business Combination
is executed by the Company (the “Allocation Notice”), which amount shall be no more than $50,000,000, in the
Purchaser's sole discretion, and (y) $10.00 (the “Number of Forward Purchase Shares”), for an aggregate purchase
price of $10.00 multiplied by the Number of Forward Purchase Shares issued and sold hereunder (the “FPS Purchase Price”).

 

     

     

    

 

(ii) The
Company shall deliver written notice to the Purchaser as early as practicable, and in any case at least eleven (11) Business Days before
the funding of the FPS Purchase Price to the Escrow Account (defined below), specifying the anticipated date of the Business Combination
Closing, the aggregate FPS Purchase Price and instructions for wiring the FPS Purchase Price to an account (the “Escrow Account”)
of a third-party escrow agent, which shall be the Company’s transfer agent (the “Escrow Agent”), pursuant
to an escrow agreement between the Company and the Escrow Agent (the “Escrow Agreement”). Two (2) Business
Days before the anticipated date of the Business Combination Closing specified in such written notice, the Purchaser shall deliver the
FPS Purchase Price in cash via wire transfer to the account specified in such written notice, to be held in escrow pending the Business
Combination Closing. If the Business Combination Closing does not occur within thirty (30) days after the Purchaser delivers the FPS Purchase
Price to the Escrow Agent, the Escrow Agreement will provide that the Escrow Agent shall automatically return to the Purchaser the FPS
Purchase Price; provided that the return of the FPS Purchase Price placed in escrow shall not terminate the Agreement or otherwise relieve
either party of any of its obligations hereunder. The Purchaser agrees that it shall cooperate in good faith and use reasonable best efforts
to effect the funding of the FPS Purchase Price on such notice as necessary to facilitate the consummation of the proposed Business Combination.
For the purposes of this Agreement, “Business Day” means any day, other than a Saturday or a Sunday, that is
neither a legal holiday nor a day on which banking institutions are generally authorized or required by law or regulation to close in
the City of New York, New York.

 

(iii) The
closing of the sale of the Forward Purchase Securities (the “FPS Closing”) shall be held on the same date as,
and immediately prior to, the Business Combination Closing (such date being referred to as the “Closing Date”).
At the FPS Closing, the Company will issue to the Purchaser the Forward Purchase Securities, registered in the name of the Purchaser,
against (and concurrently with) release of the FPS Purchase Price by the Escrow Agent to the Company.

 

     

     

    

 

(b) Delivery
of Forward Purchase Securities.

 

(i) The
Company shall register the Purchaser as the owner of the Forward Purchase Securities purchased by the Purchaser hereunder in the register
of members of the Company (in respect of the Ordinary Shares) and with the Company’s transfer agent by book entry on or promptly
after (but in no event more than two (2) Business Days after) the date of the FPS Closing.

 

(ii) Each
register and book entry for the Forward Purchase Securities purchased by the Purchaser hereunder shall contain a notation, and each certificate
(if any) evidencing the Forward Purchase Securities shall be stamped or otherwise imprinted with a legend, in substantially the following
form:

 

“THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR
OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS.”

 

(c) Legend
Removal. If the Forward Purchase Securities are eligible to be sold without restriction under Rule 144 under the Securities Act
of 1933, as amended (the “Securities Act”), then at the Purchaser’s request in connection with a sale
of such Forward Purchase Securities, the Company will, at its sole expense, cause the Company’s transfer agent to remove the legend
set forth in Section 1(b)(ii) hereof. In connection therewith, if required by the Company’s transfer agent, the Company
will promptly cause an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations,
certificates and directions required by the transfer agent, that authorize and direct the transfer agent to transfer such Forward Purchase
Securities without any such legend; provided, however, that the Company will not be required to deliver any such opinion, authorization
or certificate or direction if it reasonably believes that removal of the legend could reasonably be expected to result in or facilitate
transfers of Forward Purchase Securities in violation of applicable law.

 

(d) Registration
Rights. The Purchaser shall have registration rights with respect to the Forward Purchase Securities as set forth on Exhibit A
(the “Registration Rights”).

 

2. Representations
and Warranties of the Purchaser. The Purchaser represents and warrants to the Company as follows, as of the date hereof:

 

(a) Organization
and Power. The Purchaser is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation
(if the concept of “good standing” is a recognized concept in such jurisdiction) and has all requisite power and authority
to carry on its business as presently conducted and as proposed to be conducted.

 

(b) Authorization.
The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser,
will constitute the valid and legally binding obligation of the Purchaser, enforceable in accordance with its terms, except (i) as
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration
Rights may be limited by applicable federal or state securities laws.

 

     

     

    

 

(c) Governmental
Consents and Filings. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation
of the transactions contemplated by this Agreement.

 

(d) Compliance
with Other Instruments. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser
of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its organizational
documents, if applicable, (ii) of any instrument, judgment, order, writ or decree to which it is a party or by which it is bound,
(iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement,
contract or purchase order to which it is a party or by which it is bound or (v) of any provision of federal or state statute, rule or
regulation applicable to the Purchaser, in each case (other than clause (i)), which would have a material adverse effect on the Purchaser
or its ability to consummate the transactions contemplated by this Agreement.

 

(e) Purchase
Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company,
which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Forward Purchase Securities to be
acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation
in, or otherwise distributing the same in violation of law. By executing this Agreement, the Purchaser further represents that the Purchaser
does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations
to such Person or to any third Person, with respect to any of the Forward Purchase Securities. If the Purchaser was formed for the specific
purpose of acquiring the Forward Purchase Securities, each of its equity owners is an accredited investor as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act. For purposes of this Agreement, “Person” means an individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity
or any government or any department or agency thereof.

 

(f) Disclosure
of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the
terms and conditions of the offering and sale of the Forward Purchase Securities, as well as the terms of the IPO, with the Company’s
management.

 

(g) Restricted
Securities. The Purchaser understands that the offer and sale of the Forward Purchase Securities to the Purchaser has not been, and
will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities
Act that depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations
as expressed herein. The Purchaser understands that the Forward Purchase Securities are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Forward Purchase Securities indefinitely
unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements
is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Forward Purchase Securities, or
any Ordinary Shares that the Forward Purchase Securities may be converted into or exercised for, for resale, except pursuant to the Registration
Rights. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned
on various requirements including, but not limited to, the time and manner of sale, the holding period for the Forward Purchase Securities,
and requirements relating to the Company that are outside of the Purchaser’s control, and which the Company is under no obligation
and may not be able to satisfy. The Purchaser acknowledges that the Company filed the Registration Statement for the IPO with the SEC.
The Purchaser understands that the offering of the Forward Purchase Securities hereunder is not, and is not intended to be, part of the
IPO, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act with respect to such offering
of the Forward Purchase Securities.

 

     

     

    

 

(h) No
Public Market. The Purchaser understands that no public market now exists for the Forward Purchase Securities, and that the Company
has made no assurances that a public market will ever exist for the Forward Purchase Securities.

 

(i) High
Degree of Risk. The Purchaser understands that its agreement to purchase the Forward Purchase Securities involves a high degree of
risk which could cause the Purchaser to lose all or part of its investment.

 

(j) Accredited
Investor. The Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act.

 

(k) Foreign
Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the U.S. Internal Revenue Code
of 1986, as amended), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction
in connection with any invitation to subscribe for the Forward Purchase Securities or any use of this Agreement, including (i) the
legal requirements within its jurisdiction for the purchase of the Forward Purchase Securities, (ii) any foreign exchange restrictions
applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax
and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Forward Purchase
Securities. The Purchaser’s subscription and payment for and continued beneficial ownership of the Forward Purchase Securities will
not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

 

(l) No
General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either
directly or indirectly, including through a broker or finder, (i) to its knowledge, engaged in any general solicitation, or (ii) published
any advertisement in connection with the offer and sale of the Forward Purchase Securities.

 

(m) Residence.
The principal place of business of the Purchaser is the office located at the address of the Purchaser set forth on the signature page hereof.

 

     

     

    

 

(n) Non-Public
Information. The Purchaser acknowledges its obligations under applicable securities laws with respect to the treatment of material
non-public information relating to the Company.

 

(o) Adequacy
of Financing. The Purchaser has, or will have, from and after receipt of capital commitments not subject to opt-out rights (or for
which the party with such opt-out rights has agreed to fund in respect of this Agreement) in an aggregate amount not less than the FPS
Purchase Price, available to it sufficient funds to satisfy its obligations under this Agreement.

 

(p) Affiliation
of Certain FINRA Members. The Purchaser is neither a person associated nor affiliated with any underwriter of the IPO or, to its actual
knowledge, any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating in
the IPO.

 

(q) No
Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this Section 2
and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser
nor any of the Purchaser’s affiliates (the “Purchaser Parties”) has made, makes or shall be deemed to
make any other express or implied representation or warranty with respect to the Purchaser and the offering, sale and purchase of the
Forward Purchase Securities, and the Purchaser Parties disclaim any such representation or warranty. Except for the specific representations
and warranties expressly made by the Company in Section 3 of this Agreement and in any certificate or agreement delivered pursuant
hereto, the Purchaser Parties specifically disclaim that they are relying upon any other representations or warranties that may have been
made by the Company, any person on behalf of the Company or any of the Company’s affiliates (collectively, the “Company
Parties”).

 

3. Representations
and Warranties of the Company. The Company represents and warrants to the Purchaser as follows:

 

(a) Incorporation
and Corporate Power. The Company is an exempted company duly incorporated and validly existing and in good standing under the laws
of the Cayman Islands and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed
to be conducted. The Company has no subsidiaries.

 

(b) Capitalization.
The authorized share capital of the Company consists, as of the date hereof, of:

 

(i) 479,000,000
Class A Ordinary Shares, none of which are issued and outstanding;

 

(ii) 20,000,000
Class B ordinary shares of the Company, par value $0.0001 per share (“Class B Shares”), 3,593,750of
which are issued and outstanding; and all of the issued and outstanding Class B ordinary shares of the Company have been duly authorized,
are fully paid and nonassessable and were issued in compliance with all applicable laws and the Charter; and

 

(iii) 1,000,000
preference shares, none of which are issued and outstanding.

 

     

     

    

 

(c) Authorization.
All corporate action required to be taken by the Company’s Board of Directors and shareholders in order to authorize the Company
to enter into this Agreement, and to issue the Forward Purchase Securities at the FPS Closing, and the securities issuable upon conversion
or exercise of the Forward Purchase Securities, has been taken or will be taken prior to the FPS Closing, as applicable. All action on
the part of the shareholders, directors and officers of the Company necessary for the execution and delivery of this Agreement, the performance
of all obligations of the Company under this Agreement to be performed as of the FPS Closing, and the issuance and delivery of the Forward
Purchase Securities and the securities issuable upon conversion or exercise of the Forward Purchase Securities has been taken or will
be taken prior to the FPS Closing, as applicable. This Agreement, when executed and delivered by the Company, shall constitute the valid
and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the
Registration Rights may be limited by applicable federal or state securities laws.

 

(d) Valid
Issuance of Forward Purchase Securities.

 

(i) The
Forward Purchase Securities, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this
Agreement and the Charter and registered in the register of members of the Company, and the securities issuable upon conversion or exercise
of the Forward Purchase Securities, when issued in accordance with the terms of the Forward Purchase Securities and this Agreement and
the Charter (in respect of the Forward Purchase Shares), and registered in the register of members of the Company, will be validly issued,
fully paid and nonassessable and free of all preemptive or similar rights, liens, encumbrances and charges with respect to the issue thereof
and restrictions on transfer other than restrictions on transfer specified under this Agreement, applicable state and federal securities
laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchaser in
this Agreement and subject to the filings described in Section 3(e) below, the Forward Purchase Securities will be issued in
compliance with all applicable federal and state securities laws.

 

(ii) No
 “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification
Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below),
except for a Disqualification Event as to which Rule 506(d)(2)(ii)—(iv) or (d)(3), is applicable. “Company
Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated
under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

(e) Governmental
Consents and Filings. Assuming the accuracy of the representations and warranties made by the Purchaser in this Agreement, no consent,
approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local
governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by
this Agreement, except for any filings pursuant to Regulation D of the Securities Act, applicable state securities laws, and pursuant
to the Registration Rights.

 

     

     

    

 

(f) Compliance
with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated
by this Agreement by the Company will not result in any violation or default (i) of any provisions of the Company’s amended
and restated memorandum and articles of association, as they may be amended and/or restated from time to time (the “Articles”),
(ii) of any instrument, judgment, order, writ or decree to which the Company is a party or by which the Company is bound, (iii) under
any note, indenture or mortgage to which the Company is a party or by which the Company is bound, (iv) under any lease, agreement,
contract or purchase order to which the Company is a party or by which the Company is bound or (v) of any provision of federal or
state statute, rule or regulation applicable to the Company, in each case (other than clause (i)) which would have a material adverse
effect on the Company or its ability to consummate the transactions contemplated by this Agreement.

 

(g) Operations.
As of the date hereof, the Company has not conducted, and prior to the IPO Closing the Company will not conduct, any operations other
than organizational activities and activities in connection with the IPO and offering of the Forward Purchase Securities.

 

(h) Foreign
Corrupt Practices. Neither the Company, nor, to the knowledge of the Company, any director, officer, agent, employee or other Person
acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct
or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is
in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate,
payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

 

(i) Compliance
with Anti-Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements and all applicable U.S. and non-U.S. anti- money laundering laws, rules and regulations,
including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the USA Patriot Act of 2001 and the applicable
money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering
Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(j) Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of
the Company’s officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such.

 

     

     

    

 

(k) No
General Solicitation. Neither the Company, nor any of its officers, directors, employees, agents or shareholders has either directly
or indirectly, including through a broker or finder, (i) engaged in any general solicitation, or (ii) published any advertisement
in connection with the offer and sale of the Forward Purchase Securities.

 

(l) No
Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this Section 3
and in any certificate or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make
any other express or implied representation or warranty with respect to the Company, the offering, sale and purchase of the Forward Purchase
Securities, the IPO or a potential Business Combination, and the Company Parties disclaim any such representation or warranty. Except
for the specific representations and warranties expressly made by the Purchaser in Section 2 of this Agreement and in any certificate
or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they are relying upon any other representations
or warranties that may have been made by any of the Purchaser Parties.

 

4. Additional Agreements,
Acknowledgements and Waivers of the Purchaser.

 

(a) Trust
Account.

 

(i) The
Purchaser hereby acknowledges that it is aware that the Company will establish a trust account (the “Trust Account”)
for the benefit of its public shareholders upon the IPO Closing. The Purchaser, for itself and its affiliates, hereby agrees that it has
no right, title, interest or claim of any kind in or to any monies held in the Trust Account, or any other asset of the Company as a result
of any liquidation of the Company, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Ordinary
Shares issued in the IPO (the “Public Shares”) held by it.

 

(ii) The
Purchaser hereby agrees that it shall have no right of set-off or any right, title, interest or claim of any kind (“Claim”)
to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it
may have now or in the future, except for redemption and liquidation rights, if any, the Purchaser may have in respect of any Public Shares
held by it. In the event the Purchaser has any Claim against the Company under this Agreement, the Purchaser shall not pursue such Claim
against the Trust Account or against the property or any monies in the Trust Account, except for redemption and liquidation rights, if
any, the Purchaser may have in respect of any Public Shares held by it.

 

(b) No
Short Sales. The Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf or pursuant to any understanding
with it, will engage in any Short Sales with respect to securities of the Company prior to the Business Combination Closing. For purposes
of this Section 4(b), “Short Sales” shall include, without limitation, all “short sales” as
defined in Rule 200 promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part
of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return
basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

 

     

     

    

 

(c) Allocation
Notice. The Purchaser shall deliver the Allocation Notice to the Company immediately upon the allocation to this Agreement of capital
which has been committed to the Purchaser (in accordance with all binding obligations of the Purchaser), which in no event shall be later
than five (5) Business Days prior to such time as any definitive agreement with respect to a Business Combination is executed by
the Company.

 

5. Additional Agreements
of the Company.

 

(a) No
Material Non-Public Information. The Company agrees that no information provided to the Purchaser in connection with this Agreement
will, upon the IPO Closing, constitute material non-public information of the Company.

 

(b) Nasdaq
Listing. The Company will use commercially reasonable efforts to effect and maintain the listing of the Ordinary Shares on The Nasdaq
Capital Market (or another national securities exchange).

 

(c) No
Amendments to the Articles. The amended and restated memorandum and articles of association of the Company will be in substantially
the form attached to the Registration Statement and will not be amended in any material respect prior to the IPO Closing without the Purchaser’s
prior written consent.

 

6. FPS Closing
Conditions.

 

(a) The
obligation of the Purchaser to purchase the Forward Purchase Securities at the FPS Closing under this Agreement shall be subject to the
fulfillment, at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws,
may be waived by the Purchaser:

 

(i) The
Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Forward Purchase
Securities;

 

(ii) The
Company shall have delivered to such Purchaser a certificate evidencing the Company’s good standing as a Cayman Islands exempted
company, as of a date within ten (10) Business Days of the Closing Date;

 

(iii) The
representations and warranties of the Company set forth in Section 3 of this Agreement shall have been true and correct as of the
date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and
warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified
date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a
material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement;

 

     

     

    

 

(iv) The
Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Company at or prior to the FPS Closing; and

 

(v) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any governmental,
regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward Purchase Securities.

 

(b) The
obligation of the Company to sell the Forward Purchase Securities at the FPS Closing under this Agreement shall be subject to the fulfillment,
at or prior to the FPS Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived
by the Company:

 

(i) The
Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Forward Purchase
Securities;

 

(ii) The
representations and warranties of the Purchaser set forth in Section 2 of this Agreement shall have been true and correct as of the
date hereof and shall be true and correct as of the FPS Closing, as applicable, with the same effect as though such representations and
warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified
date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a
material adverse effect on the Purchaser or its ability to consummate the transactions contemplated by this Agreement;

 

(iii) The
Purchaser shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the FPS Closing; and

 

(iv) No
order, writ, judgment, injunction, decree, determination, or award shall have been entered or threatened by or with any governmental,
regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition
shall be in effect or threatened, preventing the purchase by the Purchaser of the Forward Purchase Securities.

 

7. Termination.
This Agreement may be terminated at any time prior to the FPS Closing:

 

(a) by
mutual written consent of the Company and the Purchaser; or

 

     

     

    

 

(b) automatically:

 

(i) if
the IPO is not consummated on or prior to twelve months from the date of this Agreement; or

 

(ii) if the Business Combination
is not consummated within twelve (12) months from the IPO Closing (or up to 18 months from the consummation of the IPO if the Company
extends the period of time to consummate a business combination), or such later date as may be approved by the Company’s shareholders
in accordance with the Articles.

 

In
the event of any termination of this Agreement pursuant to this Section 7, the FPS Purchase Price (and interest thereon, if any),
if previously paid, and all Purchaser’s funds paid in connection herewith shall be promptly returned to the Purchaser in accordance
with written instructions provided by the Purchaser to the Company, and thereafter this Agreement shall forthwith become null and void
and have no effect, without any liability on the part of the Purchaser or the Company and their respective directors, officers, employees,
partners, managers, members, or shareholders and all rights and obligations of each party shall cease; provided, however, that nothing
contained in this Section 7 shall relieve either party from liabilities or damages arising out of any fraud or willful breach by
such party of any of its representations, warranties, covenants or agreements contained in this Agreement. Section 4(a) shall
survive termination of this Agreement.

 

8. General Provisions.

 

(a) Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt, or (i) hand delivery to the party to be notified, (ii) when sent, if sent by electronic
mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business
Day or (iii) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next Business Day delivery, with written verification of receipt. All communications sent to the Company shall be sent to

 

Aries
I Acquisition Corporation

23
Lime Tree Bay, P.O. Box 1569 

Grand
Cayman, Cayman Islands KY-1110

Attention:
Randy Brinkley

 

with
a copies to the Company’s counsel at:

 

Winston &
Strawn LLP

200
Park Avenue

New
York, NY 10166

Attn:
David A. Sakowitz, Esq.

Email:
dsakowitz@winston.com

 

     

     

    

 

All
communications to the Purchaser shall be sent to the Purchaser’s address as set forth on the signature page hereof, or to such
e-mail address, facsimile number (if any) or address as subsequently modified by written notice given in accordance with this Section 8(a).

 

(b) No
Finder’s Fees. Other than fees payable to the underwriters of the IPO or any other investment bank or financial advisor who
assists the Company in sourcing targets for a Business Combination, which fees shall be the responsibility of the Company, each party
represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. The
Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of
a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability
or asserted liability) for which the Purchaser or any of its officers, employees or representatives is responsible. The Company agrees
to indemnify and hold harmless the Purchaser from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability)
for which the Company or any of its officers, employees or representatives is responsible.

 

(c) Survival
of Representations and Warranties. All of the representations and warranties contained herein shall survive the FPS Closing.

 

(d) Entire
Agreement. This Agreement, together with any documents, instruments and writings that are delivered pursuant hereto or referenced
herein, constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes
all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in
any way to the subject matter hereof or the transactions contemplated hereby.

 

(e) Successors.
All of the terms, agreements, covenants, representations, warranties, and conditions of this Agreement are binding upon, and inure to
the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express or implied,
is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f) Assignments.
Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its rights, interests, or
obligations hereunder without the prior written consent of the other party. Notwithstanding the foregoing, the Purchaser may assign and
delegate all or a portion of its rights and obligations to purchase the Forward Purchase Securities to one or more other persons upon
the consent of the Company (which consent shall not be unreasonably conditioned, withheld or delayed); provided, however, that no consent
of the Company shall be required if such assignment or delegation is to an affiliate of the Purchaser; provided, further, that no such
assignment or delegation shall relieve the Purchaser of its obligations hereunder (including its obligation to purchase the Number of
Forward Purchase Shares hereunder) and the Company shall be entitled to pursue all rights
and remedies against the Purchaser subject to the terms and conditions hereof.

 

     

     

    

 

(g) Counterparts.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute
one and the same instrument.

 

(h) Headings.
The section headings contained in this Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation
of this Agreement.

 

(i) Governing
Law. This Agreement, the entire relationship of the parties hereto, and any dispute between the parties (whether grounded in contract,
tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of
New York, without giving effect to its choice of laws principles.

 

(j) Jurisdiction.
The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York and to the jurisdiction
of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising
out of or based upon this Agreement, (ii) agree not to commence any suit, action or other proceeding arising out of or based upon
this Agreement except in state courts of New York or the United States District Court for the Southern District of New York, and (iii) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it
is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution,
that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper
or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

(k) WAIVER
OF JURY TRIAL. THE PARTIES HERETO HEREBY WAIVE ANY RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION PURSUANT TO THIS AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED HEREBY.

 

(l) Amendments.
This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of the Company
and the Purchaser.

 

(m) Severability.
The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the
validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party hereto
or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in accordance with its
terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such determination will have the power
to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases,
and in its reduced form, such provision will then be enforceable and will be enforced.

 

(n) Expenses.
Each of the Company and the Purchaser will be responsible for payment of its own costs and expenses incurred in connection with the preparation,
execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses
of agents, representatives, financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer
agent; stamp taxes and all of The Depository Trust Company’s fees associated with the issuance and resale of the Forward Purchase
Securities and the securities issuable upon conversion or exercise of the Forward Purchase Securities.

 

     

     

    

 

(o) Construction.
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent
or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of
proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. Any reference
to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and regulations promulgated
thereunder, unless the context requires otherwise. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be
construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the
context otherwise requires. The words “this Agreement,” “herein,” “hereof,” “hereby,”
 “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless
expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent
significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that
there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity)
which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation,
warranty, or covenant.

 

(p) Waiver.
No waiver by any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not,
may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in
any way any rights arising because of any prior or subsequent occurrence.

 

(q) Specific
Performance. The Purchaser agrees that irreparable damage may occur in the event any provision of this Agreement was not performed
by the Purchaser in accordance with the terms hereof and that the Company shall be entitled to specific performance of the terms hereof,
in addition to any other remedy at law or equity.

 

[Signature Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date first set forth above.

 

PURCHASER: 

 

Terra Carta Partners,
LLC

 

	By:	 	 
	 	 	 
	Name:	 	 
	Title:	  

	 

 

Address for Notices:

 

 

Attention:

 

Email:

 

COMPANY: 

 

Aries I Acquisition
Corporation

 

	By:	 	 
	 	 	 
	Name:	 	 
	Title:	  

	 

 

[Signature Page to
Forward Purchase Agreement]

 

     

     

     

[Exhibit A]

 

Registration Rights

 

1.
Within thirty (30) days after the Business Combination Closing, the Company shall use reasonable best efforts (i) to file a registration
statement on Form S-3 for a secondary offering (including any successor registration statement covering the resale of the Registrable
Securities, a “Resale Shelf”) of (x) the Ordinary Shares comprising the Forward Purchase Securities and (y) any other equity security of the Company issued or issuable with
respect to the securities referred to in clause (x) by way of a share capitalization or share split or in connection with a combination
of shares, recapitalization, merger, consolidation or reorganization (collectively, for so long as such securities are held by the Purchaser
or its assignees under the Agreement (each, a “Holder”), the “Registrable Securities”)
pursuant to Rule 415 under the Securities Act; provided that if Form S-3 is unavailable for such a registration, the Company
shall register the resale of the Registrable Securities on another appropriate form and undertake to register the Registrable Securities
on Form S-3 as soon as such form is available, (ii) to cause the Resale Shelf to be declared effective under the Securities
Act promptly thereafter, but in no event later than sixty (60) days after the initial filing of the Resale Shelf, and (iii) to maintain
the effectiveness of such Resale Shelf with respect to the Registrable Securities until the earliest of (A) the date on which such
securities are no longer Registrable Securities and (B) the date all of the Registrable Securities covered by the Resale Shelf can
be sold publicly without restriction or limitation under Rule 144 under the Securities Act and without the requirement to be in compliance
with Rule 144(c)(1) under the Securities Act.

 

2.
The Holders may, after the Resale Shelf becomes effective, deliver a written notice to the Company (the “Underwritten Offering
Notice”) specifying that the sale of some or all of the Registrable Securities subject to the Resale Shelf is intended to
be conducted through a firm commitment underwritten offering (an “Underwritten Offering”); provided, however,
that the Holders of Registrable Securities may not, without the Company’s prior written consent, (i) launch an Underwritten
Offering the anticipated gross proceeds of which shall be less than $10,000,000 (unless the Holders are proposing to sell all of their
remaining Registrable Securities), (ii) launch more than three Underwritten Offerings at the request of the Holders within any three-hundred
sixty-five (365) day-period or (iii) launch an Underwritten Offering within the period commencing fourteen (14) days prior to and
ending two (2) days following the Company’s scheduled earnings release date for any fiscal quarter or year. In the event of
an Underwritten Offering, the Holders representing a majority-in-interest of the Registrable Securities to be included in such Underwritten
Offering shall select the managing underwriter(s) for the Underwritten Offering; provided that the choice of such managing underwriter(s) shall
be subject to the consent of the Company, which is not to be unreasonably withheld, conditioned or delayed. If the underwriter(s) for
any Underwritten Offering pursuant to this paragraph 2 of this Exhibit A (each, a “Secondary Offering”)
advise the Company and the Holders that, in their good faith opinion, marketing factors require a limitation on the number of securities
that may be included in such Secondary Offering, the number of securities to be so included shall be allocated as follows: (i) first,
to the Holders that have requested to participate in such Secondary Offering, allocated pro rata among such Holders on the basis of the
percentage of the Registrable Securities requested to be included in such Secondary Offering by such Holders, and (ii) second, to
the holders of any other securities of the Company that have been requested to be so included.

 

     

     

    

 

3.
Upon receipt of prior written notice by any Holder that they intend to effect a sale of Registrable Securities held by them as are then
registered pursuant to the Resale Shelf, the Company shall use its reasonable best efforts to cooperate in such sale (whether or not such
sale constitutes an Underwritten Offering), including by amending or supplementing the prospectus related to such Resale Shelf as may
be reasonably requested by such Holder for so long as such Holder holds Registrable Securities.

 

4.
In the event the Company is prohibited by applicable rule, regulation or interpretation by the staff (the “Staff”)
of the SEC from registering all of the Registrable Securities on the Resale Shelf or the Staff requires that any Holder be specifically
identified as an “underwriter” in order to permit such registration statement to become effective, and such Holder does not
consent in writing to being so named as an underwriter in such registration statement, the number of Registrable Securities to be registered
on the Resale Shelf will be reduced on a pro rata basis among all Holders to be so included, unless otherwise required by the Staff, so
that the number of Registrable Securities to be registered is permitted by the Staff and such Holder is not required to be named as an
 “underwriter”; provided, that any Registrable Securities not registered due to this paragraph 4 shall thereafter as soon as
allowed by the SEC guidance be registered to the extent the prohibition no longer is applicable.

 

5.
If at any time the Company proposes to file a registration statement (a “Registration Statement”) on its own
behalf, or on behalf of any other Persons who have registration rights (“Other Holders”), relating to an Underwritten
Offering of ordinary shares (a “Company Offering”), then the Company will provide the Holders with notice in
writing (an “Offer Notice”) at least three (3) Business Days prior to such filing, which Offer Notice will
offer to include in the Registration Statement the Registrable Securities held by each Holder (the “Piggyback Securities”).
Within three (3) Business Days after receiving the Offer Notice, each Holder may make a written request (a “Piggyback
Request”) to the Company to include some or all of such Holder’s Registrable Securities in the Registration Statement.
If the underwriter(s) for any Company Offering advise the Company that, in their good faith opinion, marketing factors require a
limitation on the number of securities that may be included in the Company Offering, the number of securities to be so included shall
be allocated as follows: (i) first, to the Company and the Other Holders, if any; and (ii) second, to the Holders and any other
holders of similar piggyback rights, based pro rata on the value of the securities requested to be sold in such Company Offering by each
requesting holder. By written notice delivered to the Company, any Holder (an “Opting-Out Holder”) may elect
to waive its right to participate in Company Offerings (“Registration Opt-Out”) until such time as such written
notice is rescinded in writing. During such time as a Registration Opt-Out is in effect: (x) the Opting-Out Holder shall not receive
notices of any proposed Company Offering and (y) shall not be entitled to participate in any such Company Offering.

 

6.
In connection with any Underwritten Offering, the Company shall enter into such customary agreements and take all such other actions in
connection therewith (including those requested by Holders representing a majority-in-interest of the Registrable Securities to be included
in such Underwritten Offering) in order to facilitate the disposition of such Registrable Securities as are reasonably necessary or required,
and in such connection enter into a customary underwriting agreement that provides for customary opinions, comfort letters and officer’s
certificates and other customary deliverables.

 

     

     

    

 

7.
The Company shall pay all fees and expenses incident to the performance of or compliance with its obligation to prepare, file and maintain
the Resale Shelf (including the fees of its counsel and accountants). The Company shall also pay all Registration Expenses. For purposes
of this paragraph 7, “Registration Expenses” shall mean the out-of-pocket expenses of any Secondary Offering
and any Company Offering, including, without limitation, the following: (i) all registration and filing fees (including fees with
respect to filings required to be made with FINRA and any securities exchange on which the Registrable Securities are then listed); (ii) fees
and expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the underwriters
in connection with blue sky qualifications of the Registrable Securities); (iii) printing, messenger, telephone and delivery expenses;
(iv) reasonable fees and disbursements of counsel for the Company; (v) reasonable fees and disbursements of all independent
registered public accountants of the Company; and (vi) reasonable fees and expenses of one (1) legal counsel selected by Holders
representing a majority-in-interest of the Registrable Securities participating in any such Secondary Offering, but shall not include
any incremental selling expenses relating to the sale of Registrable Securities, such as underwriters’ commissions and discounts,
brokerage fees and underwriter marketing costs; and provided that the Company shall only be responsible for expenses under clause (vi) with
respect to two Secondary Offerings in any consecutive three-hundred sixty-five (365) day-period.

 

8.
The Company may suspend the use of a prospectus included in the Resale Shelf by furnishing to the Holders a written notice (“Suspension
Notice”) stating that in the good faith judgment of the Company, it would be either (i) prohibited by the Company’s
insider trading policy (as if the Holders were covered by such policy) or (ii) materially detrimental to the Company and its shareholders
for such prospectus to be used at such time. The Company’s right to suspend the use of such prospectus under clause (ii) of
the preceding sentence may be exercised for a period of not more than ninety (90) days after the date of such notice to the Holders; provided
that such period may be extended for an additional thirty (30) days with the consent of Holders representing a majority-in-interest of
the Registrable Securities, which consent shall not be unreasonably withheld; provided further, that such right to suspend the use of
a prospectus shall be exercised by the Company not more than once in any twelve (12) month period. The Holders shall not effect any sales
of Registrable Securities pursuant to the Resale Shelf at any time after they have received a Suspension Notice from the Company and prior
to receipt of an End of Suspension Notice (as defined below). The Holders may recommence effecting sales of the Registrable Securities
pursuant to the Resale Shelf following further written notice to such effect (an “End of Suspension Notice”)
from the Company to the Holders. The Company shall act in good faith to permit any suspension period contemplated by this paragraph 8
to be concluded as promptly as reasonably practicable.

 

     

     

    

 

9.
The Holders agree that, except as required by applicable law, the Holders shall treat as confidential the receipt of any Suspension Notice
(provided that in no event shall such notice contain any material non-public information of the Company) hereunder and shall not disclose
or use the information contained in such Suspension Notice without the prior written consent of the Company until such time as the information
contained therein is or becomes public, other than as a result of disclosure by a Holder of Registrable Securities in breach of the terms
of this Agreement.

 

10.
The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and
each person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses
(including attorneys’ fees) caused by any untrue or alleged untrue statement of material fact contained in the Resale Shelf (or
any amendment or supplement thereto), the related prospectus or any amendment thereof or supplement thereto or any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as
the same are caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein.

 

11.
The Company’s obligation under paragraph 1 of this Exhibit A is subject to each Holder furnishing to the Company in writing
such information as the Company reasonably requests for use in connection with the Resale Shelf, the related prospectus, or any amendment
or supplement thereto. Each Holder shall indemnify the Company, its officers, directors, managers, employees, agents and representatives,
and each person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and
expenses resulting from any untrue statement or alleged untrue statement of material fact contained in the Resale Shelf, the related prospectus,
or any amendment or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information
so furnished in writing by such Holder expressly for inclusion in such Resale Shelf, related prospectus or amendment or supplement thereto,
as applicable; provided that the obligation to indemnify shall be individual, not joint and several, and shall be limited to the net amount
of proceeds received by the applicable Holder from the sale of Registrable Securities pursuant to the Resale Shelf.

 

12.
The Company shall cooperate with the Holders, to the extent the Registrable Securities become freely tradable, to facilitate the timely
preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant
to a Resale Shelf and enable such certificates to be in such denominations or amounts, as the case may be, as the Holders may reasonably
request and registered in such names as each Holder may request.

 

     

     

    

 

13.
If requested by Holders representing a majority-in-interest of the Registrable Securities, the Company shall as soon as practicable, subject
to any Suspension Notice, (i) incorporate in a prospectus supplement or post-effective amendment such information as each Holder
reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation,
information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any
other terms of the offering of the Registrable Securities to be sold in such offering; (ii) make all required filings of such prospectus
supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective
amendment; and (iii) supplement or make amendments to any Registration Statement if reasonably requested by Holders representing
a majority-in-interest of the Registrable Securities.

 

14.
As long as Registrable Securities are outstanding, the Company, at all times while it shall be reporting under the Exchange Act, covenants
to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed
by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act, and to promptly furnish the Holders
with true and complete copies of all such filings, unless filed through the SEC’s EDGAR system. The Company further covenants that
it shall take such further action as the Holders may reasonably request, all to the extent required from time to time, to enable the Holders
to sell the Ordinary Shares and Forward Purchase Warrants held by the Holders without registration under the Securities Act within the
limitation of the exemptions provided by Rule 144 promulgated under the Securities Act, including providing any legal opinions, to
the extent such exemption is available to the Purchaser at such time. Upon the request of any Holder, the Company shall deliver to such
Holder a written certification of a duly authorized officer as to whether it has complied with such requirements.EX-10.2

 Exhibit 10.2 

CHANGE IN CONTROL RETENTION AGREEMENT 

This Change in Control Retention Agreement (this “Agreement”) is entered into as of May 10, 2021, by and between
Organogenesis Holdings Inc., a Delaware corporation with its principal offices located at 85 Dan Road, Canton, Massachusetts 02021 (together with its successors and assigns, the “Company”), and Gary S. Gillheeney, Sr. (the
“Executive”). 
 WHEREAS, the Executive is currently employed by the Company as Chief Executive Officer and President; and

 WHEREAS, the Board of Directors of the Company (the “Board”), after a recommendation from the Compensation Committee of
the Board, has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the possibility, threat or occurrence of a Change in
Control (as defined below) of the Company; 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the
parties agree as follows: 
 1.    Termination of Employment Following a Change in Control. 

1.1.     Definition of Terms 

(a)    “Accelerated Vesting Benefit” shall mean that, notwithstanding anything to the contrary in any
applicable option agreement or stock-based award agreement, all time-based stock options and other time-based stock-based awards held by the Executive shall immediately accelerate and become fully exercisable, vested or nonforfeitable as of the date
of the Executive’s termination of employment with the Company. 
 (b)    ”Change in Control”
shall mean the occurrence of any of the following: (i) the acquisition other than by the Control Group by an individual, entity, group or any other person of beneficial ownership of more than fifty percent (50%) or more of either
(x) the then-outstanding shares of common stock of the Company or (y) the combined voting power of the election of directors for the Company; and/or (ii) the sale of substantially all of the Company’s assets or a merger or sale
of stock wherein the holders of the Company’s capital stock immediately prior to such sale do not hold at least a majority of the outstanding capital stock of the Company or its successor immediately following such sale; (iii) the
Company’s stockholders approve and complete any plan or proposal for the liquidation or dissolution of the Company; and/or (iv) individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for
any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequently to the date hereof whose election, or nomination for election by the Company’s stockholders, was approved by a
vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of
office occurs as result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board. 

 (c)    “Continuation Benefits” shall consist of
the Company paying the difference between the cost of COBRA continuation coverage, should the Executive elect to receive it, for the Executive and any dependent who received health insurance coverage prior to termination of the Executive’s
employment with the Company, and any premium contribution amount applicable to the Executive as of such termination, for a period of 24 months following the date of termination of the Executive’s employment with the Company. Continuation
Benefits otherwise receivable by the Executive will be reduced to the extent benefits of the same type are received by him or her during the applicable 24-month period (and any such benefits received by the
Executive shall be reported by him or her to the Company). 
 (d)    “Control Group” means the
stockholders of the Company who are parties as of the date hereof to the Controlling Stockholders’ Agreement by and among such stockholders and the Company dated as of December 10, 2018. 

(e)    An “Event of Constructive Termination” shall mean the occurrence of any of the following events
at any time during the 24-month period following the occurrence of a Change in Control: 
  

	 	(i)	 a relocation of the Executive’s principal workplace to a location more than 50 miles from the location of
such workplace immediately prior to the Change in Control without the Executive’s express written consent; 

  

	 	(ii)	 a material diminution in the Executive’s authority, duties or responsibilities, provided that, a material
diminution of the Executive’s authority, duties or responsibilities shall be deemed to have occurred if the Executive ceases to have such authorities, duties or responsibilities with respect to the entity which is the ultimate parent entity of
the Company following a Change in Control; 

  

	 	(iii)	 a material diminution in the Executive’s compensation or benefits without the express written consent of
the Executive; or 

  

	 	(iv)	 any other action or inaction that constitutes a material breach by the Company of any written agreement under
which the Executive provides services to the Company; 

 provided, that no such event or occurrence shall constitute an
Event of Constructive Termination unless (x) written notice thereof is given by the Executive to the Company within ninety (90) days of its occurrence, (y) the Company shall fail to remedy or cure such event or occurrence within
thirty (30) days following its receipt of such notice from the Executive, and (z) the Executive shall within sixty (60) days after the expiration of such 30-day period give written notice to the
Company of the Executive’s election to terminate the Executive’s employment pursuant to this paragraph by reason of such event or occurrence. 

  
 2 

 (f)    “Severance Amount” shall be an amount equal to
two times the sum of (i) the Executive’s base annual salary and (ii) the Executive’s annual target bonus, in each case at the highest rate in effect at any time during the 12 months immediately preceding the termination of the
Executive’s employment with the Company. 
 1.2.    Termination for Cause. In the event of termination of
the Executive’s employment for Cause following a Change in Control, all compensation of the Executive and any other rights the Executive may have under this Agreement shall cease upon the termination date of his or her employment, the Executive
shall receive no Severance Amount, no Continuation Benefits, no Accelerated Vesting Benefit and no further payments or benefits shall be paid or payable to the Executive by the Company for any period thereafter, except to the extent that the
Executive shall have accrued benefits under any retirement plan adopted by the Company for the benefit of its employees and except for all compensation owing hereunder to the Executive as of the date of termination for Cause. 

For purposes of this Agreement, “Cause” shall mean: 

(a)    the Executive has been charged by the United States or a state or political subdivision thereof with conduct which
is a felony or which is a misdemeanor involving moral turpitude, deceit, dishonesty or fraud under the laws of the United States or any state or political subdivision thereof; 

(b)    fraud or embezzlement by the Executive with respect to funds of the Company or dishonest, unethical or improper
conduct by the Executive that has had, or is reasonably likely to have, a material adverse impact on the reputation for honesty and fair dealing of the Company; 

(c)    the Executive’s failure to comply with lawful instructions not inconsistent with this Agreement given to the
Executive by the Board, which failure is not cured or corrected within thirty (30) days after the Executive’s receipt of written notice from the Company referring to this paragraph and describing with specificity the instructions with
which the Executive did not comply; 
 (d)    the Executive’s material failure to comply with reasonable policies,
directives, standards and regulations adopted by the Company, including, without limitation, the Company’s policies regarding insider trading, except any such failure, that, if capable of cure, is remedied by the Executive within thirty
(30) days after the Executive’s receipt of written notice from the Company referring to this paragraph and describing with specificity the failure of the Executive to comply; and 

(e)    material breach by the Executive of the Invention, Non-Disclosure and Non-Competition Agreement by and between the Executive and the Company (the “Employee Agreement”) or any other written agreement between the Executive and the Company, except any such breach, that,
if capable of cure, is remedied by the Executive within thirty (30) days after the Executive’s receipt of written notice from the Company referring to this paragraph and describing with specificity the breach by the Executive. 

  
 3 

 1.3.    Voluntary Termination by Executive. 

(a)    The Executive may voluntarily terminate the Executive’s employment at any time by written notice to the
Company, in which case the Executive shall receive no Severance Amount, no Continuation Benefits, no Accelerated Vesting Benefit and no further payments or benefits shall be paid or payable to the Executive by the Company for any period after such
termination of employment, except to the extent that the Executive shall have accrued benefits under any plan adopted by the Company for the benefit of its employees generally and except for all compensation owing hereunder to the Executive as of
the date of voluntary termination. 
 (b)    Notwithstanding the foregoing, upon the occurrence of an Event of
Constructive Termination the Executive may, by written notice to the Company pursuant to clause (z) of Section 1.1(e) above, voluntarily terminate his or her employment with the Company, and in such event: (i) within ten
(10) days of the date of such termination, the Company shall pay to the Executive in a lump sum the Severance Amount, plus all other compensation, including, without limitation, any commissions earned but not yet paid, owed by the Company to
the Executive as of the date of his or her termination; (ii) the Company shall provide to the Executive the Continuation Benefits for a period of 24 months following such termination; and (iii) the Executive shall receive the Accelerated
Vesting Benefit as of such date of termination. 
 1.4.    Termination by the Company without Cause Following a
Change in Control. In the event that the Executive’s employment under this Agreement is terminated by the Company other than for Cause at any time during the 24-month period following a Change in
Control, then: (i), on the date of such termination, the Company shall pay to the Executive in a lump sum the Severance Amount, plus all other compensation, including, without limitation, any commissions earned but not yet paid, owed by the Company
to the Executive as of the date of his or her termination; (ii) the Company shall provide to the Executive the Continuation Benefits for a period of 24 months following such termination; and (iii) the Executive shall receive the
Accelerated Vesting Benefit as of such date of termination. 
 2.    Other Provisions. 

2.1.    Amounts Payable Less Withholding Taxes. The amounts payable by the Company hereunder shall be less any
applicable withholding for federal, state or local income and employment taxes. 
 2.2.    Parachute Payments. In
the event that the Severance Amount, the Continuation Benefits, the Accelerated Vesting Benefits and other benefits provided for in this Agreement or otherwise payable to the Executive (i) constitute “parachute payments” within the
meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the
Executive’s benefits under this Agreement shall be either: 
 (a)    delivered in full, or 

  
 4 

 (b)    delivered as to such lesser extent which would result in no
portion of such benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by the Executive on an after–tax
basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. If a reduction in severance and other benefits constituting “parachute payments” is
necessary so that benefits are delivered to a lesser extent, reduction will occur in the following order: reduction of cash payments, cancellation of equity awards granted within the 12-month period prior to a
“change in control” (as determined under Code Section 280G) that are deemed to have been granted contingent upon the change in control (as determined under Code Section 280G), cancellation of accelerated vesting of equity awards,
reduction of employee benefits. 
 Unless the Company and the Executive otherwise agree in writing, any determination required under this
Section shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making
the calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Section 280G and 4999
of the Code. The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the
Accountants may reasonably incur in connection with any calculations contemplated by this Section. 

2.3.    Section 409A. It is intended that this Agreement comply with or be exempt from
Section 409A of the Code and the Treasury Regulations and IRS guidance thereunder (collectively referred to as “Section 409A”). Notwithstanding anything to the contrary in this Agreement, this Agreement
shall, to the maximum extent possible, be administered, interpreted, and construed in a manner consistent with Section 409A. If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this
Agreement on account of termination of the Executive’s employment shall be made unless and until the Executive has a “separation from service” within the meaning of Section 409A. If any provision of this Agreement provides for
payment within a time period, the determination of when such payment shall be made within such time period shall be solely in the discretion of the Company; provided, however, that if for the period for providing and not revoking a Release at
Section 2.4 below spans two calendar years, no payment shall be made until the second calendar year. In the case of any amounts payable under this Agreement that may be treated as payable in the form of “a series of installment
payments,” as defined in Treasury Regulation Section 1.409A-2(b)(2)(iii), the right to receive such payments shall be treated as a right to receive a series of separate payments for purposes of such
Treasury Regulation. If the Executive is a “specified employee” as determined pursuant to Section 409A as of the date of termination of employment and if any payment or benefit provided for in this Agreement or otherwise both
(x) constitutes a “deferral of compensation” within the meaning of Section 409A and (y) cannot be paid or provided in the manner otherwise provided without subjecting the Executive to additional tax, interest, or penalties
under Section 409A, then any such payment or benefit shall be delayed until the earlier of (i) the date which is six (6) months after the Executive’s “separation from 

  
 5 

 
service” within the meaning of Section 409A for any reason other than death, or (ii) the date of the Executive’s death. Any payment or benefit otherwise payable or to be
provided to the Executive upon or in the six (6) month period following “separation from service” that is not so paid or provided by reason of this Section 2.3 shall be accumulated and paid or provided to the Executive in a
single lump sum, as soon as practicable (and in all events within 15 days) after the date that is six (6) months after the Executive’s “separation from service” (or, if earlier, as soon as practicable, and in all events within
fifteen (15) days, after the date of the Executive’s death). All subsequent payments or benefits, if any, shall be payable or provided in accordance with the payment schedule applicable to each payment or benefit. It is the intent of
this Agreement to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder shall be subject to the additional tax imposed under Section 409A, and any ambiguities herein shall
be interpreted to so comply. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions that are necessary, appropriate or desirable to avoid imposition of any
additional tax or income recognition prior to actual payment to the Executive under Section 409A. 

2.4.    Noncompetition Agreement and Release. It shall be a condition to the receipt by the Executive of any
payment or benefit pursuant to this Agreement that the Executive shall have executed and delivered to the Company a noncompetition agreement (the “Noncompetition Agreement”) in substantially the form attached as Exhibit A
hereto, and a general release (the “Release”) in substantially the form attached as Exhibit B hereto. The Executive acknowledges and agrees that the Employee Agreement, except to the extent superseded by the Noncompetition
Agreement, is a binding and enforceable obligation of the Executive that inures to the benefit of the Company’s successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its
assets or business in a Change in Control. The timing of any payment or benefit pursuant to this Agreement shall be governed by the following provisions. The Executive must execute and deliver the Release within 21 days after termination of
employment. If the Executive has revocation rights, such rights must be exercised, if at all, not later than seven days after execution of the Release. The Executive shall not receive the Severance Amount nor the Continuation Benefits unless and
until any revocation period has expired and the Release is effective. 
 2.5.    Notices. Any notice or other
communication required or permitted hereunder shall be in writing and shall be deemed given when delivered personally (including by overnight courier) or, if sent by regular mail, three days after the date of deposit in the United States mails
addressed as follows: 
 (a)    if to the Company, to: 

Organogenesis Holdings Inc. 
 85
Dan Road 
 Canton, Massachusetts 02021 

Attention: Chair of the Compensation Committee 

(b)    if to the Executive, to the address set forth on the signature page hereto; 

  
 6 

 or to such other address as either party may from time to time provide to the other by notice as provided in
this section. 
 2.6.     Entire Agreement. This Agreement and the other agreements between the Executive and
the Company referred to in this Agreement constitute the entire agreement and understanding between the Company and the Executive regarding the subject matter hereof, and supersede all prior negotiations, agreements, arrangements, and
understandings, both written or oral, between the Company and the Executive with respect to the subject matter of this Agreement. 

2.7.     Waiver or Amendment. 

(a)    The waiver by either party of a breach or violation of any term or provision of this Agreement by the other party
shall not operate or be construed as a waiver of any subsequent breach or violation of any provision of this Agreement or of any other right or remedy. 

(b)    No provision in this Agreement may be amended unless such amendment is set forth in a writing that specifically
refers to this Agreement and is signed by the Executive and the Company. 
 2.8.     Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of The Commonwealth of Massachusetts without regard to its conflict of laws rules. 

2.9.     Successors; Assignment. The Company shall require any successor via a Change in Control (whether direct
or indirect, by purchase, merger, consolidation or otherwise) to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.
This Agreement shall inure to the benefit of, and shall be binding upon, each of the Company and the Executive and their respective heirs, personal representatives, legal representatives, successors and assigns. 

2.10.    Severability. The invalidity of any one or more of the words, phrases, sentences, clauses or sections
contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part hereof. If any part of this Agreement shall be declared invalid by a court of competent jurisdiction, this Agreement shall be
construed as if such invalid part had not been inserted. 
 2.11.    Section Headings. The section and
subsection headings contained in this Agreement are for reference purposes only and shall not affect any way the meaning, construction or interpretation of any or all of the provisions of this Agreement. 

2.12.    Counterparts. This Agreement may be executed in any number of counterparts and by the separate parties
hereto in separate counterparts, each of which shall be deemed to constitute an original and all of which shall be deemed to be one and the same instrument. 

  
 7 

 2.13.    Authority to Execute. The undersigned representative of
the Company represents and warrants that he has full power and authority to enter into this Agreement on behalf of the Company, and that the execution, delivery and performance of this Agreement have been authorized by the Board. Upon the
Executive’s acceptance of this Agreement by signing and returning it to the Company, this Agreement will become binding upon the Executive and the Company. 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first written above. 

 

							
	EXECUTIVE	 		 	                                   
 ORGANOGENESIS HOLDINGS INC.

							
				
	 /s/ Gary S. Gillheeney, Sr.
	 	                	 	By:	 	 /s/ Lori Freedman

	Name: Gary S. Gillheeney, Sr.	 		 	Name:	 	Lori Freedman
		 		 	Title:	 	Vice President and General Counsel

  
 8 

 Exhibit A 

NONCOMPETE AGREEMENT 
 This
NONCOMPETE AGREEMENT (the “AGREEMENT”), made as of the [    ] day of [                ], is entered into between Organogenesis
Holdings Inc., a Delaware corporation with offices at 85 Dan Road, Canton, Massachusetts 02021 (the “Company”) and [                ] (the
“Employee”). 
 RECITALS: 

A.    The Company is willing to grant certain severance and other benefits to the Employee, under the circumstances
specified in that certain Change in Control Retention Agreement dated [    ], 2021 between the Company and the Employee (the “Change in Control Agreement”); and 

B.    As set forth in the Change in Control Agreement, the Employee’s execution of this Agreement is a condition to
the Employee’s receipt of such benefits; 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	1.	 NON-COMPETITION COVENANTS. 

(a)    NON-COMPETITION COVENANTS. The Employee agrees that he or
she will not, during the Non-Competition Period (as hereinafter defined), directly or indirectly: 

(i)    as owner, employee, officer, director, partner, sales representative, agent, stockholder, capital
investor, lessor, consultant or advisor, either alone or in association with others (other than as a holder of not more than one percent of the outstanding shares of any series or class of securities of a company, which securities of such class or
series are publicly traded in the securities markets), develop, design, produce, market, sell or render (or assist any other person or entity in developing, designing, producing, marketing, selling or rendering), products or services which are
competitive with the Business of the Company (as hereinafter defined) anywhere in the world; 

(ii)    solicit, divert or take away, or attempt to solicit, divert or take away, the business or patronage
of any of the customers, prospective customers or referral sources of the Company with whom the Company has had a relationship during the period of the Employee’s employment by the Company; or 

(iii)    recruit, solicit or hire any employee of the Company, or induce or attempt to induce any employee
of the Company to terminate his or her employment with, or otherwise cease his or her relationship with, the Company. 

  
 9 

 (b)    DEFINITIONS. For the purposes of this
Section 1, the following terms shall have the respective meanings indicated below: 

(i)    “NON-COMPETITION PERIOD” shall mean the 24-month period commencing on the last day of the Employee’s employment by the Company. 

(ii)    “BUSINESS OF THE COMPANY” shall mean all activities of the Company, including, without
limitation, research, development, sales, engineering, financial and accounting work, IT maintenance and development, technical and clinical feasibility investigations (conducted or contemplated), governmental approvals (obtained or applied for) and
the manufacturing, fabrication, packaging, sale, distribution, or licensing of any products or services offered or contemplated to be offered by the Company in the fields of i) advanced wound care for the treatment of chronic and acute wounds,
tissue regeneration, skin substitutes, and/or the healing of musculoskeletal injuries, and ii) surgical and sports medicine. For the avoidance of doubt and without limitation, such fields shall include living and
non-living tissue and organ replacement and repair constructs, related to the sub-fields of wound repair, bio-surgery, and bio-aesthetics, including, but not limited to: (a) living dermal equivalents, living epidermal equivalents, living skin equivalents, wound coverings and wound management products; (b) living connective
tissue constructs and biomaterial constructs for the repair and/or replacement tendon, ligament, body-wall, cardiac tissue, vasculature, bone, cartilage, neural tissue; (c) injectable matrix compositions, injectable cell compositions, topical
compositions containing cytokines, growth factors, and other cell-communication compounds; (d) natural and synthesized collagen compositions, and natural and synthesized extracellular matrix compositions; (e) cell culture media for
culturing cells and living constructs; (f) stem cells; and (g) cell- delivery constructs. 
  

	2.	 INJUNCTIVE AND OTHER EQUITABLE RELIEF. 

(a)    The Employee consents and agrees that if the Employee violates any of the provisions of
Section 1 hereof, the Company shall be entitled, in addition to any other remedies it may have at law, to the remedies of injunction, specific performance and other equitable relief for a breach by the Employee of Section 1 of this
Agreement. This Section 2(a) shall not, however, be construed as a waiver of any of the rights which the Company may have for damages or otherwise. 

(b)    Any waiver by the Company of a breach of any provision of Section 1 hereof shall not operate
or be construed as a waiver of any subsequent breach of such provision or any other provision hereof. 

(c)    The Employee agrees that each provision of Section 1 shall be treated as a separate and
independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of the other clauses herein. Moreover, if one or more of the provisions contained in Section 1 shall for any reason be held to be
excessively broad as to scope, 

  
 10 

 
activity or subject so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting and reducing it or them so as to be enforceable
to the maximum extent compatible with the applicable law as it shall then appear. 
 (d)    If the Company shall prevail
in any action, suit or other proceeding (whether at law, in equity or otherwise) instituted concerning or arising out of this Agreement, it shall recover, in addition to any other remedy granted to it therein, all its costs and reasonable
attorneys’ fees incurred in connection with the prosecution or defense of such action, suit or other proceeding. 

3.    OTHER AGREEMENTS. The Employee represents and warrants that the Employee’s performance of all the terms of this
Agreement does not and will not breach any other agreement by which he is bound. 
 4.    ENTIRE AGREEMENT. This
Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. In particular, this Agreement supersedes Section [2.2]
of the Employee Agreement, but the rest of the Employee Agreement remains in full force and effect.     

5.    AMENDMENT. This Agreement may be amended or modified only by a written instrument executed by both the Company and
the Employee. 
 6.    GOVERNING LAW. This Agreement shall be construed, interpreted and enforced in accordance with the
laws of The Commonwealth of Massachusetts, without regard to its choice of law principles. The Employee hereby consents to (a) service of process, and to be sued, in The Commonwealth of Massachusetts and (b) to the jurisdiction of the
courts of The Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of any suit, action or
other proceeding arising out of any of Employee’s obligations hereunder, and Employee expressly waives any and all objections he or she may have as to venue in any such courts. 

7.    SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure to the benefit of both parties and their
respective successors and assigns, including any corporation with which or into which the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Employee are personal and shall not be
assigned by him. 
 8.    MISCELLANEOUS. 

(a)    No delay or omission by the Company in exercising any right under this Agreement shall operate as a
waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

  
 11 

 (b)    The captions of the sections of this Agreement
are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 

(c)    This Agreement shall be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision hereof shall be prohibited or invalid under any such law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating or nullifying the remainder of such provision or any other
provisions of this Agreement. If any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, such provisions shall be construed by
limiting and reducing it so as to be enforceable to the maximum extent permitted by applicable law. 
 IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the day and year set forth above. 
  

			
	ORGANOGENESIS HOLDINGS INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	EMPLOYEE
	
	  

	Name:

  
 12 

 Exhibit B 

GENERAL RELEASE AND WAIVER OF ALL CLAIMS 

(INCLUDING OLDER WORKER BENEFITS PROTECTION ACT CLAIMS) 

For good and valuable consideration, including without limitation the compensation and benefits set forth in the Change in Control Retention Agreement dated
[                ], 20__ (the “Agreement”) between the undersigned and Organogenesis Holdings Inc. (the “Company”), to which this
General Release and Waiver of All Claims is attached, the terms of which Agreement shall survive this General Release and Waiver of Claims, the undersigned, on behalf of and for himself or herself and his or her heirs, administrators, executors,
representatives, estates, attorneys, insurers, successors and assigns (hereafter referred to separately and collectively as the “Releasor”), hereby voluntarily releases and forever discharges the Company, and its subsidiaries
(direct and indirect), affiliates, related companies, divisions, predecessor and successor companies, and each of its and their present, former, and future stockholders, officers, directors, employees, agents, representatives, attorneys, insurers
and assigns (collectively as “Releasees”), jointly and individually, from any and all actions, causes of action, claims, suits, charges, complaints, contracts, covenants, agreements, promises, debts, accounts, damages, losses, sums
of money, obligations, demands, and judgments all of any kind whatsoever, known or unknown, at law or in equity, in tort, contract, by statute, or on any other basis, for contractual, compensatory, punitive or other damages, expenses (including
attorney’s fees and cost), reimbursements, or costs of any kind, which the undersigned employee ever had, now has, or may have, from the beginning of the world to the date of this Release, known or unknown, in law or equity, whether statutory
or common law, whether federal, state, local or otherwise, including but not limited to any and all claims arising out of or in any way related to the undersigned’s engagement by the Company (including the hiring or termination of that
engagement), or any related matters including, but not limited to claims, if any arising under the Age Discrimination in Employment Act of 1967, as amended by the Older Worker Benefits Protection Act; the Civil Rights Act of 1964, as amended; the
Civil Rights Act of 1991, as amended; the Family and Medical Leave Act of 1993, as amended; the Immigration Reform and Control Act of 1986; the Americans with Disabilities Act of 1990, as amended; the Employee Retirement Income Security Act (ERISA),
as amended; the Massachusetts laws against discrimination and harassment (including Mass. Gen. L. c. 151B), protecting equal rights or concerning the payment of wages (including Mass. Gen. L. c. 149, section 148 et seq. and Mass. Gen. L. c. 151,
section 1A, et seq.), and federal, state or local common law, laws, statutes, ordinances or regulations. Notwithstanding the foregoing, nothing contained in this General Release and Waiver of Claims shall be construed to bar any claim by the
undersigned to enforce the terms of the Agreement. 
 [For employees aged 40 and older: 

Releasor represents and acknowledges the following: 
  

	 	(a)	 that Releasor understands the various claims Releasor could have asserted under federal or state law, including
but not limited to the Age Discrimination in Employment Act, Mass. Gen. L. c. 151B, the Massachusetts Wage Act and Massachusetts overtime pay law and other similar laws; 

  
 13 

	 	(b)	 that Releasor has read this General Release carefully and understands all of its provisions;

  

	 	(c)	 that Releasor understands that Releasor has the right to and is advised to consult an attorney concerning this
General Release and in particular the waiver of rights Releasor might have under the laws described herein and that to the extent, if any, that Releasor desired, Releasor availed himself or herself of this right; 

 

	 	(d)	 that Releasor has been provided at least twenty-one (21) days to
consider whether to sign this General Release and that to the extent Releasor has signed this General Release before the expiration of such twenty-one (21) day period Releasor has done so knowingly and
willingly; 

  

	 	(e)	 that Releasor enters into this General Release and waives any claims knowingly and willingly; and

  

	 	(f)	 that this General Release shall become effective seven (7) days after it is signed. Releasor may revoke
this General Release within seven (7) days after it is signed by delivering a written notice of rescission to Chair of Compensation Committee, Organogenesis Holdings Inc., 85 Dan Road, Canton, Massachusetts 02021. To be effective, the notice of
rescission must be hand delivered, or postmarked within the seven (7) day period and sent by certified mail, return receipt requested, to the referenced address.] 

Signed and sealed this          day of
                    , 20    . 
  

			
	Signed:	 	  

		
	Name (print):	 	  

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]